Clinician-reviewed CDS · Browser-local · Source-linkedRead more…
This tool is educational and informational. It does not replace clinical judgment. Verify outpatient epilepsy maintenance ASM selection, spectrum coverage, and monitoring guidance against the cited source before acting.
Not prospectively validated. No clinical tool replaces bedside assessment.
This tool qualifies as non-device clinical decision support under the January 2026 FDA CDS guidance (21st Century Cures Act §3060). It does not acquire or analyze patient data, it displays the basis for its recommendations, it enables independent clinician review, and it is intended for use by trained healthcare professionals.
This runs entirely in your browser; we store nothing. Even so, enter only clinical data (age, vitals, exam findings) -- not names, MRNs, or other identifiers.
Tarvinder Singh, MD -- Vascular Neurologist. March 2026.
Epilepsy Maintenance
Outpatient antiseizure medication selection and sequencing with syndrome, reproductive, and regimen fit.
At a glance
BaselineMain options: Lamotrigine, Levetiracetam, Lacosamide, or Oxcarbazepine.
Next step
Refine with syndrome, current ASM, or reproductive risk.
Evidence
Lamotrigine
Strong first-line
Default outpatient focal first-line standard when slower titration is acceptable.
Levetiracetam
Strong first-line
Practical first-line focal and broad-spectrum option when fast titration and interaction simplicity matter.
Lacosamide
Reasonable first-line / early switch
Useful early focal option when titration speed, cleaner PK, and outpatient simplicity matter more than generalized-spectrum breadth.
Why this lane
Baseline fit
Adult focal first-line choices lead until another constraint outweighs them.
Syndrome guardrail
Generalized, absence, or myoclonic features push broad-spectrum choices up and carbamazepine-family drugs down.
Sequencing trigger
A current ASM turns this into a continue, add-on, or replace decision.
What to clarify next
No current ASM modeled
No current ASM is entered. This is an initial maintenance decision.
Different mechanisms first
If a tolerated first ASM is only partially effective, a different-mechanism add-on is usually cleaner than stacking similar mechanisms.
Sodium overlap
Two sodium-channel blockers are often less attractive than a sodium-channel blocker plus levetiracetam.
Monitoring and follow-up
Reassessment
Reassess after target dose and tolerability are established, sooner if adverse effects, wrong-spectrum clues, or ongoing seizures change the picture.
Lamotrigine
Rash counseling
Lamotrigine
Serum level when dose optimization or pregnancy shifts matter
Levetiracetam
Behavioral counseling and early mood follow-up are high value.
Lamotrigine
Strong first-line | Sodium channel; broad-spectrum behavior
Default outpatient focal first-line standard when slower titration is acceptable.
More detail
Strongest routine focal first-line choice for many adults because tolerability, cognition, and reproductive fit often outweigh the slower ramp.
Strengths: First-line focal standard | Mood stabilizing utility | Relatively cognition-friendly
Watch for: Slow titration | Rash / SJS risk | Estrogen and pregnancy increase clearance
Monitoring: Rash counseling | Serum level when dose optimization or pregnancy shifts matter
Levetiracetam
Strong first-line | SV2A binder
Practical first-line focal and broad-spectrum option when fast titration and interaction simplicity matter.
Behavioral counseling and early mood follow-up are high value.
More detail
Fast, simple, broad-spectrum option that rises with urgency, pregnancy planning, and polypharmacy, but falls with behavioral vulnerability.
Strengths: Fast titration | Minimal interaction burden | Broad-spectrum
Watch for: Irritability / hostility | Depression or anxiety worsening in some patients | Short half-life and less missed-dose forgiveness
Monitoring: Behavioral follow-up | Renal dose review
Lacosamide
Reasonable first-line / early switch | Slow sodium-channel inactivation
Useful early focal option when titration speed, cleaner PK, and outpatient simplicity matter more than generalized-spectrum breadth.
More detail
Fast, clean focal agent with less classic sodium-channel baggage, but PR-interval concerns and weaker absence/myoclonic fit still matter.
Strengths: Fast titration | Low interaction burden | Useful monotherapy or adjunctive option
Watch for: PR prolongation / conduction concern | Less attractive with absence or myoclonic concern | More adverse effects with other sodium blockers
Monitoring: Baseline or follow-up ECG when conduction disease is relevant | Renal review
Oxcarbazepine
Reasonable first-line focal | Classic sodium channel blocker
Effective focal monotherapy alternative when sodium risk, generalized concern, and contraceptive interactions are not the main issue.
More detail
Clear focal monotherapy option with XR availability, but hyponatremia, generalized-epilepsy guardrails, and contraceptive issues limit fit.
Strengths: Effective focal monotherapy | XR once-daily option | Overnight switch pathway within carbamazepine family
Watch for: Hyponatremia risk | May worsen absence or myoclonic seizures | Reduces oral contraceptive efficacy at higher doses
Monitoring: Serum sodium | Monohydroxy derivative level if needed
Eslicarbazepine
Reasonable early alternative | Sodium channel blocker
Once-daily focal sodium-channel option with cleaner tolerability than oxcarbazepine, but the same generalized and sodium guardrails still apply.
Eslicarbazepine can be a practical focal option, but it usually sits behind lamotrigine, levetiracetam, lacosamide, or oxcarbazepine in early sequencing.
More detail
Useful once-daily focal option after first-line standards, especially when a carbamazepine-family switch is being considered, but it is still narrow-spectrum.
Strengths: Once-daily dosing | Less acute peak toxicity than oxcarbazepine | Monotherapy conversion data
Watch for: Hyponatremia still occurs | Narrow-spectrum generalized guardrail | Oral contraceptive interaction
Monitoring: Serum sodium | Contraception review
Carbamazepine
Usually not first choice now | Classic sodium channel blocker
Historically strong focal standard, but interaction burden, generalized-epilepsy traps, sodium/rash monitoring, and rebound risk make it less attractive now.
Modern outpatient use of carbamazepine is often limited by enzyme induction, monitoring burden, and rebound risk.
CBC and liver enzymes are part of routine carbamazepine follow-up.
More detail
Still effective for focal epilepsy and bipolar disorder, but usually falls behind newer agents because of enzyme induction, monitoring burden, and generalized-epilepsy traps.
Strengths: Strong focal efficacy | Bipolar and trigeminal neuralgia utility | Helpful serum levels
Watch for: High interaction burden with autoinduction | HLA-B*1502 severe-rash concern | Hyponatremia, CBC/LFT burden, bone effects
Monitoring: CBC | LFTs
Zonisamide
Alternative / adherence-friendly | Sodium plus T-type calcium; carbonic anhydrase activity
Broad-spectrum-leaning alternative when once-daily dosing, weight loss, and migraine overlap matter more than cognition or stone risk.
Zonisamide is rarely the routine first choice because first-line focal data still favored lamotrigine.
More detail
Useful once-daily alternative with favorable adherence profile and weight-loss tendency, but cognitive slowing, mood risk, stones, and limited first-line footing matter.
Strengths: Long half-life / missed-dose forgiveness | Once-daily option | Weight loss tendency
Watch for: Cognitive slowing | Depression / irritability / psychosis risk | Kidney stones and metabolic acidosis
Monitoring: Hydration and stone counseling | Mood / cognition follow-up
Topiramate
Alternative / comorbidity-shaped | Multi-mechanism; carbonic anhydrase activity
Broad-spectrum alternative when weight loss or migraine comorbidity matters more than cognitive burden or reproductive concerns.
Topiramate is usually a comorbidity-shaped alternative rather than a routine first focal choice because cognitive adverse effects are common.
More detail
Can be very useful when migraine or obesity is part of the story, but cognitive burden, renal-stone risk, and reproductive tradeoffs keep it out of routine first-choice status.
Strengths: Migraine prophylaxis | Weight loss | Broad-spectrum tonic-clonic coverage
Watch for: Cognitive slowing / word-finding difficulty | Depression risk | Kidney stones / metabolic acidosis / glaucoma
Monitoring: Hydration and stone counseling | Bicarbonate or metabolic acidosis review
Brivaracetam
Adjunctive / smart substitution | SV2A binder
Best used as an SV2A-focused substitution or add-on choice, especially when levetiracetam worked but behavioral toxicity got in the way.
Brivaracetam is usually more compelling as adjunctive or later-line sequencing than as an initial focal-monotherapy pick.
Behavioral counseling and early mood follow-up are high value.
More detail
Less behaviorally toxic SV2A option with rapid onset, but it is not a compelling pair with levetiracetam and still lacks routine first-line footing.
Strengths: Useful levetiracetam substitute for behavioral toxicity | Rapid clinical response | Lower irritability signal than levetiracetam
Watch for: Not useful with levetiracetam | More interactions than levetiracetam | Mostly adjunctive / later-sequencing role
Monitoring: Behavioral follow-up | Interaction review with carbamazepine or phenytoin
Valproate
Situation-specific / generalized anchor | Broad-spectrum multi-mechanism
Broad-spectrum high-efficacy option that becomes especially attractive in generalized epilepsy outside childbearing contexts.
Valproate is not a routine focal first-choice drug unless generalized-spectrum efficacy or a special comorbidity pushes it up.
CBC, platelets, liver tests, and pregnancy counseling matter up front.
More detail
Exceptionally effective broad-spectrum drug with strong generalized-epilepsy and comorbidity utility, but high teratogenicity, weight gain, and interaction burden sharply narrow its preferred use.
Strengths: Strongest generalized-spectrum efficacy | Migraine and bipolar utility | ER once-daily option
Watch for: Highest teratogenic and neurodevelopmental concern | Weight gain / endocrine effects | High interaction burden
Monitoring: CBC / platelets | LFTs
Cenobamate
Later-line adjunctive | Persistent sodium-current plus GABA modulation
Early drug-resistant focal adjunctive option with exceptional efficacy, but its slow titration, interaction burden, and later-line positioning keep it out of routine first-agent decisions.
Cenobamate is usually more compelling as adjunctive or later-line sequencing than as an initial focal-monotherapy pick.
Slow titration and interaction review are part of safe cenobamate use.
More detail
Stands out for high seizure-free rates in drug-resistant focal epilepsy, but it belongs in later sequencing and requires slow titration plus active interaction management.
Strengths: Exceptional adjunctive focal efficacy | Long half-life / daily dosing | Often cognition-neutral in studies
Watch for: Very slow titration | High interaction complexity | Can reduce contraceptive efficacy
Monitoring: Slow titration to reduce DRESS risk | Interaction review with clobazam, phenytoin, phenobarbital, lamotrigine, and contraception